Retatrutide Linked to Arrhythmias, Cardio Risks
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly disclosed safety and tolerability findings for its obesity drug retatrutide at the American Diabetes Association annual meeting and in the Lancet.
- Retatrutide was evaluated in the late‑stage TRANSCEND‑T2D‑1 study, where participants with diabetes achieved significant weight loss and blood‑sugar reduction.
- Arrhythmias occurred in 7 of 403 participants receiving retatrutide, while none were reported in the placebo arm.
- Major cardiovascular complications were observed in 3 participants treated with retatrutide, compared with zero events in the placebo group.
Why it matters: Patients with diabetes using retatrutide have increased cardiac risk, and Eli Lilly faces tighter regulatory scrutiny and slower market launch. Safety concerns also impact investor confidence and pricing strategies.
